Spero Therapeutics, Inc. (SPRO) Q1 2024 Earnings
SPRO·Reported May 15, 2024·After market close
Spero Therapeutics, Inc. reported Q1 2024 revenue of $4.2M, missed analyst consensus of $21.5M by $17.3M. Diluted EPS came in at $-0.24, missed the $-0.07 consensus by $0.17.
Revenue
$4.2Mmissed by $17.3M
Consensus: $21.5MDiluted EPS
$-0.24missed by $0.17
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Spero Therapeutics, Inc.'s Q1 2024 earnings report.
Spero Therapeutics, Inc. (SPRO) reported Q1 2024 earnings on May 15, 2024 after market close.
Spero Therapeutics, Inc. reported revenue of $4.2M and diluted EPS of $-0.24 for Q1 2024.
Revenue missed the consensus estimate of $21.5M by $17.3M. EPS missed the consensus estimate of $-0.07 by $0.17.
You can read the 10-Q periodic report (0000950170-24-060400) directly on SEC EDGAR. The filing index links above go to sec.gov.